Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 184

The DOI matches its Crossref record.

Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma

Open access
Kunii, Naoki, Horiguchi, Shigetoshi, Motohashi, Shinichiro, Yamamoto, Heizaburo, Ueno, Naoyuki, Yamamoto, Seiji, Sakurai, Daiju, Taniguchi, Masaru, Nakayama, Toshinori, Okamoto, Yoshitaka·2009·Cancer Science

Abstract

The aim of this clinical trial was to investigate the feasibility of intra‐arterial infusion of in vitro‐expanded Vα24 natural killer T (NKT) cells combined with submucosal injection of α‐galactosylceramide (KRN7000; αGalCer)‐pulsed antigen‐presenting cells (APC). A phase I clinical study was carried out in patients with head and neck squamous cell carcinoma (HNSCC). Patients with locally recurrent HNSCC refractory to standard therapy were eligible. Eight patients received super‐selective transcatheter intra‐arterial infusion of activated Vα24 NKT cells into tumor‐feeding arteries and nasal submucosal injections of αGalCer‐pulsed APC twice with a 1‐week interval. Vα24 NKT cell‐specific immune responses, safety, and antitumor effects were evaluated. The number of Vα24 NKT cells and interferon‐γ‐producing cells in peripheral blood mononuclear cells increased in seven out of eight patients enrolled. Grade 3 toxicity with a pharyngocutaneous fistula related to local tumor reduction was observed in one patient and mild adverse events with grade 1–2 symptoms occurred in seven patients. Regarding the clinical responses, three cases exhibited a partial but significant response, four were classified as stable disease, and one patient continued to develop progressive disease. The use of the intra‐arterial infusion of activated Vα24 NKT cells and the submucosal injection of αGalCer‐pulsed APC has been shown to induce significant antitumor immunity and had beneficial clinical effects in the management of advanced HNSCC. The use of such therapeutic modalities may be helpful in the management of tumors and therefore needs to be explored in further detail. The clinical trial registration number was UMIN000000722. (Cancer Sci 2009; 100: 1092–1098)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1349-7006.2009.01135.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 184

Metadata

Authors
Kunii, N., Horiguchi, S., Motohashi, S., Yamamoto, H., Ueno, N., Yamamoto, S., Sakurai, D., Taniguchi, M., Nakayama, T., & Okamoto, Y.
Venue
Cancer Science
Publisher
Wiley
Published
2009-05-20
Volume
100
Issue
6
Pages
1092-1098
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2034857439
Cited by
184
References
0
FWCI
5.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma. https://app.cochat.ai/papers/10.1111/j.1349-7006.2009.01135.x
The paper
Kunii, N., Horiguchi, S., Motohashi, S., Yamamoto, H., Ueno, N., Yamamoto, S., Sakurai, D., Taniguchi, M., Nakayama, T., & Okamoto, Y. (2009). Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma. Cancer Science. https://doi.org/10.1111/j.1349-7006.2009.01135.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.